The HALT study for cats.
Study details.
This study will investigate the efficacy of a new medication for the treatment of Hypertrophic Cardiomyopathy (HCM) in cats.
Inclusion criteria:
Cats must meet the following:
- Weigh ≥ 2.5 kg (5.5 lb) and be ≥ 18 months and < 15 years at enrollment
- Be willing to take oral medications
- Have a diagnosis of HCM confirmed by echocardiography
- Have an elevation of cardiac biomarkers (NTproBNP)
- Be otherwise healthy (e.g. non-diabetic, no chronic infections)
Exclusion criteria:
Exclusion criteria include but are not limited to:
- Cannot be pregnant, nursing, or intended for breeding
- Cannot have advanced or symptomatic HCM
- No other serious concurrent medical conditions
Locations and contacts:
- Reno, NV: Catherine Gunther-Harrington, DVM, DACVIM (Cardiology) at 775.358.8555
Duration of study.
5 visits over 12 months.
Covered costs.
All study-related costs including exams, diagnostics, and procedures are covered by the study sponsor.
